History
2013
Founded by Amir Jafri
January 2014
Terumo BCT, an industry-leading manufacturer of therapeutic apheresis equipment, and Immunicom enter into a strategic partnership
May 2014
Start of pre-clinical canine trial
December 2015
Completed a $5.5M Series A Preferred Stock financing
February 2016
The pre-clinical canine cancer trial ended, achieving 300 Immunopheresis treatments. Overall, 50-60% of the canine patients treated were observed to have either a stable disease or partial response. One canine experienced a complete response with clearance of metastases.
December 2017
University of California San Diego and Immunicom entered an exclusive licensing agreement to co-develop targeted molecule delivery technology
May 2018
The U.S. FDA awards Immunicom Breakthrough Device Designation for the treatment of cancer
August 2018
Immunicom leaders co-authored peer reviewed article in The Journal of Translational Medicine on unleashing TNF-alpha as a cancer immunotherapeutic
June 2019
First patient enrolled in a multi-center clinical trial at University of Krakow to investigate the outcomes of Immunopheresis as a treatment for patients with triple negative breast cancer
July 2019
Immunicom hosted the First Annual Global Immunopheresis Conference in Krakow, Poland
July 2020
First patient enrolled in a clinical trial at Sheba Medical Center to investigate the outcomes of ImmunopheresisTM as a monotherapy and combination therapy. The trial is assessing metastatic melanoma, triple negative breast cancer, renal cell carcinoma and non-small cell lung cancer
March 2021
The ImmunopheresisTM LW-02 column received regulatory clearance (CE Mark certification) in Europe for use in adults with advanced, refractory triple negative breast cancer (TNBC)
Get in touch today
Let’s talk about what we can achieve together